Jun Xiao
Jun Xiao has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Tahsin Tarik Torsha
Southern Medical University, Guangzhou, 510515, Guangdong Province, China
2 shared publications Yong Hu
Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, China
2 shared publications- Yong Hu
Fang Yu, BD, Department of Joint Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, GuangZhou City, GuangDong Province, China
2 shared publications - Zhan-Jun Shi
Department of Orthopaedic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong Province, China
2 shared publications Zhi-Fa Huang
Department of Orthopaedics & Traumatology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong Province, People's Republic of China
2 shared publications- Aibin Liang
Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine
1 shared publication
Latest Publications
- Open Access
- 3 April 2025
- Published by AccScience Publishing in Tumor Discovery
- Vol. 4 (2) , 4
The role of melanoma-derived exosomes in metastasis: Challenges and opportunities
Melanoma, a highly aggressive skin cancer, is characterized by its strong metastatic potential and resistance to standard treatments. Recent cancer research has emphasized the significance of exosomes, a type of extracellular vesicle and particle, in mediating cell-to-cell communication and driving tumor progression. Melanoma-derived exosomes contribute to metastasis by facilitating immune evasion, modulating the tumor microenvironment, and inducing epithelial-to-mesenchymal transition. The exosomal cargos, including nucleic acids (DNA, microRNA, long noncoding RNA, and circular RNA), proteins, lipids, and other biomolecules, play critical roles in reprogramming recipient cells to support tumor growth and spread. These exosomes also aid in forming pre-metastatic niches by transferring pro-inflammatory cytokines, extracellular matrix remodeling enzymes, and angiogenic factors to distant organs, preparing these sites for tumor colonization. Furthermore, tumor-derived exosomes promote therapy resistance by delivering drug-resistant molecular signatures, which diminish treatment efficacy. This emerging evidence highlights the therapeutic potential of exosome-based strategies, including inhibitors of exosome biogenesis and uptake or the use of engineered exosomes for targeted drug delivery. Advances in precision medicine also facilitate the use of exosome-derived molecular signatures in early-stage diagnosis and treatment monitoring through liquid biopsy. However, clinical translation remains challenging due to cargo heterogeneity, lack of standardized isolation methods, and potential off-target effects in exosome-based therapies. Addressing these challenges could lead to more effective therapies and better patient outcomes. This review synthesizes current knowledge on the biogenesis, composition, and functional roles of tumor-derived exosomes in metastasis, alongside their potential applications as biomarkers and therapeutic strategies. Deciphering exosomal dynamics in melanoma may open new avenues for advanced diagnostics and treatments.
- 3 April 2025
- Published by AccScience Publishing in Tumor Discovery
- Vol. 4 (2) , 4
Open AccessThe role of melanoma-derived exosomes in metastasis: Challenges and opportunities
Melanoma, a highly aggressive skin cancer, is characterized by its strong metastatic potential and resistance to standard treatments. Recent cancer research has emphasized the significance of exosomes, a type of extracellular vesicle and particle, in mediating cell-to-cell communication and driving tumor progression. Melanoma-derived exosomes contribute to metastasis by facilitating immune evasion, modulating the tumor microenvironment, and inducing epithelial-to-mesenchymal transition. The exosomal cargos, including nucleic acids (DNA, microRNA, long noncoding RNA, and circular RNA), proteins, lipids, and other biomolecules, play critical roles in reprogramming recipient cells to support tumor growth and spread. These exosomes also aid in forming pre-metastatic niches by transferring pro-inflammatory cytokines, extracellular matrix remodeling enzymes, and angiogenic factors to distant organs, preparing these sites for tumor colonization. Furthermore, tumor-derived exosomes promote therapy resistance by delivering drug-resistant molecular signatures, which diminish treatment efficacy. This emerging evidence highlights the therapeutic potential of exosome-based strategies, including inhibitors of exosome biogenesis and uptake or the use of engineered exosomes for targeted drug delivery. Advances in precision medicine also facilitate the use of exosome-derived molecular signatures in early-stage diagnosis and treatment monitoring through liquid biopsy. However, clinical translation remains challenging due to cargo heterogeneity, lack of standardized isolation methods, and potential off-target effects in exosome-based therapies. Addressing these challenges could lead to more effective therapies and better patient outcomes. This review synthesizes current knowledge on the biogenesis, composition, and functional roles of tumor-derived exosomes in metastasis, alongside their potential applications as biomarkers and therapeutic strategies. Deciphering exosomal dynamics in melanoma may open new avenues for advanced diagnostics and treatments.
- Open Access
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 4564-4565
Phase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma
Background: Zevorcabtagene autoleucel (Zevor-cel, CT053), a fully human autologous anti- B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 4564-4565
Open AccessPhase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma
Background: Zevorcabtagene autoleucel (Zevor-cel, CT053), a fully human autologous anti- B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell
- 6 March 2022
- Published by Springer Nature in International Orthopaedics
- Vol. 46 (6) , 1323-1330
Analysis of peripheral bone reconstruction after the failure of hip osteonecrosis treatment with porous tantalum rod implantation
Purpose Failure of porous tantalum rod (PTR) implantation in treating early osteonecrosis of femoral head (ONFH) has been frequently reported, but the underlying mechanism remains uncertain, which raised the concern of its efficacy. The study aimed to discuss the underlying mechanism from the perspectives of bone reconstruction and pathological changes. Methods Five patients with PTR implantation experienced total hip arthroplasty (THA) due to recurrent pain, whose femoral heads were collected as “tantalum group.” Normal (fracture) and necrotic femoral heads were respectively collected (both n = 5) after THA. The bone quality and structure, biomechanical properties, and histopathological features were analyzed by micro-CT scanning, mechanical measurement, and histological examination. Results Both the tantalum group and necrotic group had significantly poorer bone quantity and quality than the normal group. Three-dimensional imaging reconstruction showed that the trabeculae of the tantalum group were poorest in quality. Significant differences in terms of bone quality, structure, and biomechanical properties were present between the inside and outside regions around PTR, which revealed abnormal bone reconstruction. Biomechanical analysis revealed inferior properties in the tantalum group and necrosis group. H&E staining demonstrated neutrophil infiltration among the peripheral trabeculae around PTR, and the inflammation cells were significantly more abundant than that in the normal and necrosis groups. Conclusion Abnormal bone reconstruction around PTR was an important cause for failure of PTR implantation in the treatment of ONFH, which was related to biomechanical stress distribution and chronic inflammation infiltration. Insufficient biomechanical support and inflammatory trabeculae edema might account for the recurrent pain.
- 6 March 2022
- Published by Springer Nature in International Orthopaedics
- Vol. 46 (6) , 1323-1330
Analysis of peripheral bone reconstruction after the failure of hip osteonecrosis treatment with porous tantalum rod implantation
Purpose Failure of porous tantalum rod (PTR) implantation in treating early osteonecrosis of femoral head (ONFH) has been frequently reported, but the underlying mechanism remains uncertain, which raised the concern of its efficacy. The study aimed to discuss the underlying mechanism from the perspectives of bone reconstruction and pathological changes. Methods Five patients with PTR implantation experienced total hip arthroplasty (THA) due to recurrent pain, whose femoral heads were collected as “tantalum group.” Normal (fracture) and necrotic femoral heads were respectively collected (both n = 5) after THA. The bone quality and structure, biomechanical properties, and histopathological features were analyzed by micro-CT scanning, mechanical measurement, and histological examination. Results Both the tantalum group and necrotic group had significantly poorer bone quantity and quality than the normal group. Three-dimensional imaging reconstruction showed that the trabeculae of the tantalum group were poorest in quality. Significant differences in terms of bone quality, structure, and biomechanical properties were present between the inside and outside regions around PTR, which revealed abnormal bone reconstruction. Biomechanical analysis revealed inferior properties in the tantalum group and necrosis group. H&E staining demonstrated neutrophil infiltration among the peripheral trabeculae around PTR, and the inflammation cells were significantly more abundant than that in the normal and necrosis groups. Conclusion Abnormal bone reconstruction around PTR was an important cause for failure of PTR implantation in the treatment of ONFH, which was related to biomechanical stress distribution and chronic inflammation infiltration. Insufficient biomechanical support and inflammatory trabeculae edema might account for the recurrent pain.
- 8 June 2020
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 11 (1) , 279-291
Injection route affects intra-articular hyaluronic acid distribution and clinical outcome in viscosupplementation treatment for knee osteoarthritis: a combined cadaver study and randomized clinical trial
The coverage of hyaluronic acid (HA) on the impaired cartilage should be the precondition to exert its beneficial effect on knee osteoarthritis (KOA) according to the pharmacological mechanism. However, the intra-articular distribution of HA might be correlated with the route of drug delivery. Forty-two cadaver knees with radiographic evidence of osteoarthritis were given anteromedial (AM) or medial midpatellar (MMP) injection of HA (molecular weight 600–1500 kD) followed by gait stimulation. Although 2.5 ml HA delivered through both routes failed to cover the entire cartilage, HA covered 96.12% cartilage of patellofemoral joint (PFJ) and 71.44% of medial femorotibial joint (FTJ) through MMP route, whereas mainly distributed into FTJ and posterior condyles through AM route. HA in the MMP group distributed more in PFJ than that in the AM group (P < 0.001), but no significant difference presented in medial FTJ (P = 0.084). The clinical efficacy was also associated with the route of drug delivery. One hundred patients with unilateral mild-to-moderate KOA were recruited and randomly assigned to receive five weekly HA injections with AM route (n = 50) or MMP route (n = 50). Patients in the MMP group obtained better improvement in WOMAC index total score, pain score, stiffness score, and Lequesne index total score over the entire follow-up period, as compared to patients in the AM group (all P < 0.01). More patients in the MMP group claimed pain relief (71.7%, P = 0.024) and felt satisfying (63.1%, P = 0.007) than in the AM group at the end of follow-up. Therefore, intra-articular HA injection through MMP route is recommended in treating mild-to-moderate KOA. .
- 8 June 2020
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 11 (1) , 279-291
Injection route affects intra-articular hyaluronic acid distribution and clinical outcome in viscosupplementation treatment for knee osteoarthritis: a combined cadaver study and randomized clinical trial
The coverage of hyaluronic acid (HA) on the impaired cartilage should be the precondition to exert its beneficial effect on knee osteoarthritis (KOA) according to the pharmacological mechanism. However, the intra-articular distribution of HA might be correlated with the route of drug delivery. Forty-two cadaver knees with radiographic evidence of osteoarthritis were given anteromedial (AM) or medial midpatellar (MMP) injection of HA (molecular weight 600–1500 kD) followed by gait stimulation. Although 2.5 ml HA delivered through both routes failed to cover the entire cartilage, HA covered 96.12% cartilage of patellofemoral joint (PFJ) and 71.44% of medial femorotibial joint (FTJ) through MMP route, whereas mainly distributed into FTJ and posterior condyles through AM route. HA in the MMP group distributed more in PFJ than that in the AM group (P < 0.001), but no significant difference presented in medial FTJ (P = 0.084). The clinical efficacy was also associated with the route of drug delivery. One hundred patients with unilateral mild-to-moderate KOA were recruited and randomly assigned to receive five weekly HA injections with AM route (n = 50) or MMP route (n = 50). Patients in the MMP group obtained better improvement in WOMAC index total score, pain score, stiffness score, and Lequesne index total score over the entire follow-up period, as compared to patients in the AM group (all P < 0.01). More patients in the MMP group claimed pain relief (71.7%, P = 0.024) and felt satisfying (63.1%, P = 0.007) than in the AM group at the end of follow-up. Therefore, intra-articular HA injection through MMP route is recommended in treating mild-to-moderate KOA. .
- 11 March 2019
- Published by SAGE Publications in Journal of Back and Musculoskeletal Rehabilitation
- Vol. 32 (2) , 329-337
Effect of Mannitol plus Vitamins B in the management of patients with piriformis syndrome
BACKGROUND: Piriformis syndrome (PS) is an entrapment of the sciatic nerve by the piriformis muscle, or myofascial pain from the piriformis muscle. OBJECTIVE: The aim of this study was to investigate the effectiveness of “Mannitol plus Vitamins B” re
- 11 March 2019
- Published by SAGE Publications in Journal of Back and Musculoskeletal Rehabilitation
- Vol. 32 (2) , 329-337
Effect of Mannitol plus Vitamins B in the management of patients with piriformis syndrome
BACKGROUND: Piriformis syndrome (PS) is an entrapment of the sciatic nerve by the piriformis muscle, or myofascial pain from the piriformis muscle. OBJECTIVE: The aim of this study was to investigate the effectiveness of “Mannitol plus Vitamins B” re
- Open Access
- 22 December 2018
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 13 (1) , 325
Blood loss of total knee arthroplasty in osteoarthritis: an analysis of influential factors
Total knee arthroplasty is regarded as the most effective treatment for severe knee osteoarthritis. The influential factors of blood loss in total knee arthroplasty remain controversial. The study aims to explore the influential factors of blood loss in total knee arthroplasty comprehensively. Three hundred and four osteoarthritis patients undergoing unilateral primary total knee arthroplasty were enrolled. Demographic characteristics, laboratory results, surgical protocol, and hemostatic and anticoagulation drugs were collected. Estimation of blood loss was calculated using the Gross equation. Multivariable stepwise linear regression analysis was performed to find out the influential factors. Total blood loss reached the biggest volume (1346 ± 671 mL) in the post-operative third day. Hidden blood loss reached 465 ± 358 mL. Gender, tranexamic acid, prosthesis type, and drainage were proven to be positively correlated with the total blood loss (all P < 0.05). Male appeared to suffer more surgical blood loss than female. Posterior cruciate stabilizing prosthesis might lead to more surgical blood loss than posterior cruciate retaining prosthesis. Tranexamic acid could effectively reduce total blood loss while drainage might increase bleeding. Gender and anticoagulation drugs were correlated with hidden blood loss (both P < 0.05). Low molecular weight heparin resulted in less hidden blood loss than rivaroxaban. Posterior cruciate retaining prosthesis and topical use of tranexamic acid were preferred to reduce total blood loss. Drainage was not recommended due to the risk of increasing bleeding. Low molecular weight heparin was recommended to prevent venous thrombosis.
- 22 December 2018
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 13 (1) , 325
Open AccessBlood loss of total knee arthroplasty in osteoarthritis: an analysis of influential factors
Total knee arthroplasty is regarded as the most effective treatment for severe knee osteoarthritis. The influential factors of blood loss in total knee arthroplasty remain controversial. The study aims to explore the influential factors of blood loss in total knee arthroplasty comprehensively. Three hundred and four osteoarthritis patients undergoing unilateral primary total knee arthroplasty were enrolled. Demographic characteristics, laboratory results, surgical protocol, and hemostatic and anticoagulation drugs were collected. Estimation of blood loss was calculated using the Gross equation. Multivariable stepwise linear regression analysis was performed to find out the influential factors. Total blood loss reached the biggest volume (1346 ± 671 mL) in the post-operative third day. Hidden blood loss reached 465 ± 358 mL. Gender, tranexamic acid, prosthesis type, and drainage were proven to be positively correlated with the total blood loss (all P < 0.05). Male appeared to suffer more surgical blood loss than female. Posterior cruciate stabilizing prosthesis might lead to more surgical blood loss than posterior cruciate retaining prosthesis. Tranexamic acid could effectively reduce total blood loss while drainage might increase bleeding. Gender and anticoagulation drugs were correlated with hidden blood loss (both P < 0.05). Low molecular weight heparin resulted in less hidden blood loss than rivaroxaban. Posterior cruciate retaining prosthesis and topical use of tranexamic acid were preferred to reduce total blood loss. Drainage was not recommended due to the risk of increasing bleeding. Low molecular weight heparin was recommended to prevent venous thrombosis.
- 8 August 2018
- Published by Springer Nature in International Orthopaedics
- Vol. 43 (7) , 1727-1734
An evidence-based etiology study of synovial cyst of knee cruciate ligament: a real or pseudo-cyst
Synovial cyst of knee cruciate ligament (SCKCL) is a rare condition but can cause severe knee pain. The understanding of its etiology is relatively poor. This current study aimed to elucidate the pathogenesis of SCKCL based on a series of histo- and cytopathological examination.
- 8 August 2018
- Published by Springer Nature in International Orthopaedics
- Vol. 43 (7) , 1727-1734
An evidence-based etiology study of synovial cyst of knee cruciate ligament: a real or pseudo-cyst
Synovial cyst of knee cruciate ligament (SCKCL) is a rare condition but can cause severe knee pain. The understanding of its etiology is relatively poor. This current study aimed to elucidate the pathogenesis of SCKCL based on a series of histo- and cytopathological examination.
- 7 June 2017
- Published by IOP Publishing in Biomedical Materials
- Vol. 12 (3) , 035010
Systematic evaluation of the osteogenic capacity of low-melting bioactive glass-reinforced 45S5 Bioglass porous scaffolds in rabbit femoral defects
Due to the low strength and high brittleness of 45S5 Bioglass®, it is still a great challenge for the three-dimensional porous 45S5 Bioglass® to treat mechanically required loaded bone defects. Therefore, 45S5 Bioglass®-derived bioactive glass-ceramic (BGC) porous scaffolds were fabricated at a low temperature sintering condition with and without the addition of 4% low-melting ZnO/B2O3 (ZB) bioactive glass as a reinforcing agent and using 350- or 500 μm paraffin microspheres as a porogen. The pore structure characterization for the scaffolds indicated that the scaffolds containing 4% ZB had very good macroporous structures of ~313 and ~448 μm in pore size and over 70% porosity with appreciable strength (>15 MPa), which was about four times higher than that those manufactured without ZB and with 350 μm porogen scaffolds. The open porosity was decreased with the addition of 4% ZB but the interconnected pore percentage (>50 μm) was increased with increasing the porogen size from 350 to 500 μm. In vivo investigations revealed that the stronger scaffolds containing 4% ZB and 500 μm porogen were particularly beneficial for osteogenic capacity in critical size femoral bone defects, accompanied with an accelerated bone ingrowth (6–18 weeks) and the material itself experiencing mild resorption. In contrast, both the scaffolds with smaller pore sizes exhibited a low level of new bone ingrowth (®-derived BGC scaffolds in a clinical setting, especially for mechanically loaded bone defects.
- 7 June 2017
- Published by IOP Publishing in Biomedical Materials
- Vol. 12 (3) , 035010
Systematic evaluation of the osteogenic capacity of low-melting bioactive glass-reinforced 45S5 Bioglass porous scaffolds in rabbit femoral defects
Due to the low strength and high brittleness of 45S5 Bioglass®, it is still a great challenge for the three-dimensional porous 45S5 Bioglass® to treat mechanically required loaded bone defects. Therefore, 45S5 Bioglass®-derived bioactive glass-ceramic (BGC) porous scaffolds were fabricated at a low temperature sintering condition with and without the addition of 4% low-melting ZnO/B2O3 (ZB) bioactive glass as a reinforcing agent and using 350- or 500 μm paraffin microspheres as a porogen. The pore structure characterization for the scaffolds indicated that the scaffolds containing 4% ZB had very good macroporous structures of ~313 and ~448 μm in pore size and over 70% porosity with appreciable strength (>15 MPa), which was about four times higher than that those manufactured without ZB and with 350 μm porogen scaffolds. The open porosity was decreased with the addition of 4% ZB but the interconnected pore percentage (>50 μm) was increased with increasing the porogen size from 350 to 500 μm. In vivo investigations revealed that the stronger scaffolds containing 4% ZB and 500 μm porogen were particularly beneficial for osteogenic capacity in critical size femoral bone defects, accompanied with an accelerated bone ingrowth (6–18 weeks) and the material itself experiencing mild resorption. In contrast, both the scaffolds with smaller pore sizes exhibited a low level of new bone ingrowth (®-derived BGC scaffolds in a clinical setting, especially for mechanically loaded bone defects.